MS Drug Prices Far Exceed Value Thresholds, Even At Current Discounts

MS Drug Prices Far Exceed Value Thresholds, Even At Current Discounts – ICER Report

14 Feb 2017

List pricing for Biogen’s Tecfidera and Novartis’ Gilenya would need to be discounted 47% and 50%, respectively, for them to be considered good values, ICER concludes in a new report. But three products come in under ICER's thresholds.

List prices for the leading multiple sclerosis drugs should be discounted by 25% to 80% to be considered cost effective, the Institute for Clinical and Economic Review concludes in a recently released final evidence report on the treatment class.

The discount recommendations and ICER’s report are intended to help inform MS drug contracting discussions between manufacturers and payers going...